Академический Документы
Профессиональный Документы
Культура Документы
M&A
in
PHARMA
1
REASONS FOR M& A
A B C
MM.DD.20XX
3
ADD A FOOTER
The bigger picture
Gilead
HIV/AIDS therapies- 1990
“Pipeline Deals”
Hepatitis C treatments Sovaldi and Harvoni, (2011- Pharmasset)
Kite’s technology
chimeric antigen receptor T-cell (CART) therapy
Big bets on cancer
6
After a relatively quiet 12 months for
mergers and acquisitions in 2017,
this year is expected to produce a HOT COMPANIES!!!
bumper crop of deals between big
Juno and Bluebird CAR-T
pharma and biotech. drugs- $8.68bn
Spark Therapeutics- gene
therapy field-
Luxturna approved by the
WATCH OUT FOR FDA DEC 2017, $850,000
Clovis, the (Arizona)- price for the one-off treatment.
ovarian cancer space with
corporation tax Rubrca. -$3.32 billion BioMarin- gene therapy for
Puma Biotech- breast cancer haemophilia A
drug neratinib- $3.59 bn
reduce corporation tax
from 35% to 21% Sage Therapeutics- SAGE-
217 showed clear benefits in
income earned overseas – its phase 3 trial, while
these will be taxed brexanolone- Depression-
between 8 and 15.5% $6.83 billion
instead of the current 35%
7
M & A- 2018
Sanofi agreed to buy U.S. hemophilia expert Bioverativ for $11.6 billion
Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it
does not already own.
8
THANK
YOU!
: